Advertisement

Digestive Diseases and Sciences

, Volume 61, Issue 11, pp 3335–3345 | Cite as

Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis

  • Tsai-Ling Liu
  • Justin Trogdon
  • Morris Weinberger
  • Bruce Fried
  • A. Sidney BarrittIVEmail author
Original Article

Abstract

Objectives

Liver cirrhosis is a leading cause of morbidity and mortality in the USA. Diabetes is common and increasing in incidence. Patients with compensated cirrhosis and diabetes may be at greater risk of clinical decompensation. We examined the risk of decompensation among a large sample of working-aged insured patients dually diagnosed with compensated cirrhosis and diabetes.

Methods

This retrospective study used MarketScan® Commercial Claims and Encounters and Medicare Supplemental Databases (2000–2013). Decompensation events included incident ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, acute renal failure, and hepatocellular carcinoma. Dually diagnosed patients were defined as patients with cirrhosis and diabetes using previously published ICD-9 coding strategies. Adjusted odds ratios (ORs), hazard ratios (HRs), and confidence intervals (CI) were estimated using logistic regression and Cox proportional hazard models.

Results

Of 72,731 patients with compensated cirrhosis, 20,477 patients (28.15 %) were diagnosed with diabetes. After controlling for patient characteristics and medication usage, the odds of developing any decompensation event were 1.14 times higher for patients with cirrhosis and diabetes than for patients with cirrhosis only (95 % CI 1.08–1.21, P value <0.01). In the Cox proportional hazard model, patients who were dually diagnosed with diabetes had a 1.32 times higher HR (95 % CI 1.26–1.39, P value <0.01) after controlling for time-to-event.

Conclusions

Patients dually diagnosed with compensated cirrhosis and diabetes had a higher risk of having decompensation events. Careful management of diabetes in patients with liver disease may reduce the risk of clinical decompensation in this population.

Keywords

Liver diseases Multiple chronic conditions Secondary data 

Notes

Acknowledgments

The database infrastructure used for this project was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health; the Cecil G. Sheps Center for Health Services Research, UNC; the CER Strategic Initiative of UNC’s Clinical Translational Science Award (1 ULI RR025747); and the UNC School of Medicine. Tsai-Ling Liu was supported by a predoctoral Fellowship from Worldwide Health Economics and Outcomes Research at Bristol-Myers Squibb (BMS). BMS had no role in the study design, analysis, interpretation; preparation, review, approval, or decision to submit the manuscript for publication. Morris Weinberger was supported by a VA Health Services Research Senior Career Scientist Award (RCS 91-408).

Funding

This study was sponsored by a predoctoral Fellowship from Worldwide Health Economics and Outcomes Research at Bristol-Myers Squibb when the research was conducted. The funding and supporting organization had no role in the study design, analysis, interpretation of the data, preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10620_2016_4261_MOESM1_ESM.docx (920 kb)
Supplementary material 1 (DOCX 919 kb)

References

  1. 1.
    Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Murray CJL. The State of US Health, 1990–2010. JAMA. 2013;310:591–606.CrossRefPubMedGoogle Scholar
  3. 3.
    Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49:690–696.CrossRefPubMedGoogle Scholar
  4. 4.
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521.CrossRefPubMedGoogle Scholar
  5. 5.
    Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (NY). 2011;7:661–671.Google Scholar
  6. 6.
    Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61:1–32.PubMedGoogle Scholar
  7. 7.
    Charlton M. Cirrhosis and liver failure in nonalcoholic fatty liver disease: molehill or mountain? Hepatology. 2008;47:1431–1433.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Petit JM, Hamza S, Rollot F, et al. Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis. Acta Diabetol. 2014;51:455–460.PubMedGoogle Scholar
  9. 9.
    Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol. 2000;32:209–217.CrossRefPubMedGoogle Scholar
  10. 10.
    Holstein A, Hinze S, Thießen E, Plaschke A, Egberts E-H. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677–681.CrossRefPubMedGoogle Scholar
  11. 11.
    Bianchi G, Wchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology. 1994;20:119–125.PubMedGoogle Scholar
  12. 12.
    Wlazlo N, van Greevenbroek MM, Curvers J, et al. Diabetes mellitus at the time of diagnosis of cirrhosis is associated with higher incidence of spontaneous bacterial peritonitis, but not with increased mortality. Clin Sci (Lond). 2013;125:341–348.CrossRefGoogle Scholar
  13. 13.
    Butt Z, Jadoon NA, Salaria ON, et al. Diabetes mellitus and decompensated cirrhosis: risk of hepatic encephalopathy in different age groups. J Diabetes. 2013;5:449–455.CrossRefPubMedGoogle Scholar
  14. 14.
    Yang C-H, Chiu Y-C, Chen C-H, et al. Diabetes mellitus is associated with gastroesophageal variceal bleeding in cirrhotic patients. Kaohsiung J Med Sci. 2014;30:515–520.CrossRefPubMedGoogle Scholar
  15. 15.
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533–539.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    El-serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–468.CrossRefPubMedGoogle Scholar
  17. 17.
    El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology. 2002;122:1822–1828.CrossRefPubMedGoogle Scholar
  18. 18.
    Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014;60:823–831.CrossRefPubMedGoogle Scholar
  19. 19.
    CDC. Long-term Trends in Diabetes. CDC's Division of Diabetes Translation; 2014:1–6.Google Scholar
  20. 20.
    CDC. Deaths: final data for 2012. Natl Vital Stat Rep. 2012;63:1–85.Google Scholar
  21. 21.
    Hansen LG, Chang S. Health Research Data for the Real World: The MarketScan ® Databases; 2013:1–48.Google Scholar
  22. 22.
    Schmidt ML, Barritt AS, Orman ES, Hayashi PH. Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology. 2015;148:e2.CrossRefPubMedGoogle Scholar
  23. 23.
    Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs Administrative Databases. Aliment Pharmacol Ther. 2008;27:274–282.CrossRefPubMedGoogle Scholar
  24. 24.
    Iii VLR, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf. 2011;20:689–699.CrossRefGoogle Scholar
  25. 25.
    Orman ES, Hayashi PH, Bataller R, Barritt AS. Paracentesis is associated with reduced mortality in patients hospitalized with cirrhosis and ascites. Clin Gastroenterol Hepatol. 2014;12:e1.CrossRefPubMedGoogle Scholar
  26. 26.
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50.CrossRefPubMedGoogle Scholar
  27. 27.
    Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442–5460.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    du Cheyron D, Bouchet B, Parienti J-J, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med. 2005;31:1693–1699.CrossRefPubMedGoogle Scholar
  29. 29.
    Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37:233–243.CrossRefPubMedGoogle Scholar
  30. 30.
    CMS. Quality Rating System—Measure Technical Specifications; 2014:1–175.Google Scholar
  31. 31.
    Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35:2665–2673.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921–927.CrossRefPubMedGoogle Scholar
  33. 33.
    Sharabiani MTA, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data. Med Care. 2012;50:1109–1118.CrossRefPubMedGoogle Scholar
  34. 34.
    Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care. 2004;42:355–360.CrossRefPubMedGoogle Scholar
  35. 35.
    Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C trial cohort. Dig Dis Sci. 2011;56:564–568.CrossRefPubMedGoogle Scholar
  36. 36.
    Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010;53:273–282.CrossRefPubMedGoogle Scholar
  37. 37.
    Wang K-L, Liu C-J, Chao T-F, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60:1231–1238.CrossRefPubMedGoogle Scholar
  38. 38.
    Chiu H-F, Ho S-C, Chen C-C, Yang C-Y. Statin use and the risk of liver cancer: a population-based case–control study. Am J Gastroenterol. 2011;106:894–898.CrossRefPubMedGoogle Scholar
  39. 39.
    Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci. 2014;59:1958–1965.CrossRefPubMedGoogle Scholar
  40. 40.
    Skyler JS, Bergenstal R, Bonow RO, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology. J Am Coll Cardiol. 2009;53:298–304.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Tsai-Ling Liu
    • 1
  • Justin Trogdon
    • 2
  • Morris Weinberger
    • 3
    • 4
  • Bruce Fried
    • 5
  • A. Sidney BarrittIV
    • 6
    Email author
  1. 1.Department of Health Policy and Management, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Department of Health Policy and Management, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel HillUSA
  3. 3.Department of Health Policy and Management, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel HillUSA
  4. 4.Durham VAMC Center for Health Services ResearchDurhamUSA
  5. 5.Department of Health Policy and Management, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel HillUSA
  6. 6.Division of Gastroenterology and HepatologyUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations